European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): Study Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Feb 21

PMID 30782589

Citations 47

Authors

Alina Solomon

Miia Kivipelto

Jose Luis Molinuevo

Brian Tom

Craig W Ritchie

Affiliations

Soon will be listed here.

Abstract

Introduction: The European Prevention of Alzheimer's Dementia (EPAD) project is funded initially by the Innovative Medicines Initiative and has been established to overcome the major hurdles hampering drug development for secondary prevention of Alzheimer's dementia, by conducting the EPAD Longitudinal Cohort Study (LCS) in alignment with the Bayesian adaptive designed EPAD Proof-of-Concept (PoC) trial.

Methods And Analysis: EPAD LCS is an ongoing prospective, multicentre, pan-European longitudinal cohort study. Participants are recruited mainly from existing parent cohorts across Europe to form a 'probability-spectrum' population covering the entire continuum of anticipated probability for Alzheimer's dementia development. The primary objective of the EPAD LCS is to be a readiness cohort for the EPAD PoC trial though a second major objective is to generate a comprehensive and large data set for disease modelling of preclinical and prodromal Alzheimer's disease. This characterisation of cognitive, biomarker and risk factor (genetic and environmental) status of research participants over time will provide the necessary well-phenotyped population for developing accurate longitudinal models for Alzheimer's disease covering the entire disease course and concurrently create a pool of highly characterised individuals for the EPAD PoC trial.

Ethics And Dissemination: The study has received the relevant approvals from numerous Institutional Review Boards across Europe. Findings will be disseminated to several target audiences, including the scientific community, research participants, patient community, general public, industry, regulatory authorities and policy-makers. Regular and coordinated releases of EPAD LCS data will be made available for analysis to help researchers improve their understanding of early Alzheimer's disease stages and facilitate collaborations.

Trial Registration Number: NCT02804789.

Citing Articles

Accrual of Alzheimer's disease pathology as a function of proximity to parental dementia onset.

Ziukelis E, Mak E, Ritchie C, OBrien J, Aarsland D Alzheimers Dement (Amst). 2025; 17(1):e70092.

PMID: 40018326 PMC: 11865705. DOI: 10.1002/dad2.70092.

Grey-Matter Structure Markers of Alzheimer's Disease, Alzheimer's Conversion, Functioning and Cognition: A Meta-Analysis Across 11 Cohorts.

Couvy-Duchesne B, Frouin V, Bouteloup V, Koussis N, Sidorenko J, Jiang J Hum Brain Mapp. 2025; 46(2):e70089.

PMID: 39907291 PMC: 11795582. DOI: 10.1002/hbm.70089.

Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia.

Lorenzini L, Maranzano A, Ingala S, Collij L, Tranfa M, Blennow K Neurology. 2024; 103(7):e209801.

PMID: 39288341 PMC: 11450612. DOI: 10.1212/WNL.0000000000209801.

Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals.

Lorenzini L, Collij L, Tesi N, Vilor-Tejedor N, Ingala S, Blennow K Alzheimers Dement. 2024; 20(9):6146-6160.

PMID: 39073684 PMC: 11497686. DOI: 10.1002/alz.14096.

Generation Scotland: an update on Scotland's longitudinal family health study.

Milbourn H, McCartney D, Richmond A, Campbell A, Flaig R, Robertson S BMJ Open. 2024; 14(6):e084719.

PMID: 38908846 PMC: 11340249. DOI: 10.1136/bmjopen-2024-084719.

References

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Buysse D, Reynolds 3rd C, Monk T, BERMAN S, Kupfer D . The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. View

Julian L . Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S467-72. PMC: 3879951. DOI: 10.1002/acr.20561. View

Milne R, Bunnik E, Tromp K, Bemelmans S, Badger S, Gove D . Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research. J Prev Alzheimers Dis. 2017; 4(2):125-131. DOI: 10.14283/jpad.2017.5. View

Debruyne H, Van Buggenhout M, Le Bastard N, Aries M, Audenaert K, De Deyn P . Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment?. Int J Geriatr Psychiatry. 2009; 24(6):556-62. DOI: 10.1002/gps.2154. View

Tu S, Wong S, Hodges J, Irish M, Piguet O, Hornberger M . Lost in spatial translation - A novel tool to objectively assess spatial disorientation in Alzheimer's disease and frontotemporal dementia. Cortex. 2015; 67:83-94. DOI: 10.1016/j.cortex.2015.03.016. View

Hampel H, OBryant S, Castrillo J, Ritchie C, Rojkova K, Broich K . PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis. 2017; 3(4):243-259. PMC: 5363725. DOI: 10.14283/jpad.2016.112. View

Livingston G, Sommerlad A, Orgeta V, Costafreda S, Huntley J, Ames D . Dementia prevention, intervention, and care. Lancet. 2017; 390(10113):2673-2734. DOI: 10.1016/S0140-6736(17)31363-6. View

Hendrix J, Finger B, Weiner M, Frisoni G, Iwatsubo T, Rowe C . The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. Alzheimers Dement. 2015; 11(7):850-9. DOI: 10.1016/j.jalz.2015.05.008. View

10.

Sikkes S, de Lange-de Klerk E, Pijnenburg Y, Gillissen F, Romkes R, Knol D . A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012; 8(6):536-43. DOI: 10.1016/j.jalz.2011.08.006. View

11.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

12.

Molinuevo J, Cami J, Carne X, Carrillo M, Georges J, Isaac M . Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimers Dement. 2016; 12(5):614-22. PMC: 4861656. DOI: 10.1016/j.jalz.2016.01.009. View

13.

Sachdev P, Lo J, Crawford J, Mellon L, Hickey A, Williams D . STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimers Dement (Amst). 2017; 7:11-23. PMC: 5257024. DOI: 10.1016/j.dadm.2016.10.006. View

14.

Rovio S, Kareholt I, Helkala E, Viitanen M, Winblad B, Tuomilehto J . Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005; 4(11):705-11. DOI: 10.1016/S1474-4422(05)70198-8. View

15.

Weiner M, Veitch D, Aisen P, Beckett L, Cairns N, Green R . The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2016; 13(5):561-571. PMC: 5536850. DOI: 10.1016/j.jalz.2016.10.006. View

16.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

17.

Ritchie C, Molinuevo J, Truyen L, Satlin A, Van der Geyten S, Lovestone S . Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry. 2015; 3(2):179-86. DOI: 10.1016/S2215-0366(15)00454-X. View

18.

Dubois B, Feldman H, Jacova C, DeKosky S, Barberger-Gateau P, Cummings J . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46. DOI: 10.1016/S1474-4422(07)70178-3. View

19.

Jack Jr C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. PMC: 3622225. DOI: 10.1016/S1474-4422(12)70291-0. View

20.

Weintraub S, Dikmen S, Heaton R, Tulsky D, Zelazo P, Bauer P . Cognition assessment using the NIH Toolbox. Neurology. 2013; 80(11 Suppl 3):S54-64. PMC: 3662346. DOI: 10.1212/WNL.0b013e3182872ded. View